GoodRx deals may add pressure for pacts on other large PBMs, says TD Cowen

After GoodRx (GDRX) and MedImpact announced a new savings solution designed to integrate GoodRx’s prescription pricing,TD Cowen analyst Charles Rhyee noted that this represents GoodRx’s third signed partnership with a major PBM. The analyst, who sees the announcement adding pressure to other large PBMs – such as UnitedHealth’s (UNH) OptumRx, Humana (HUM) and Prime Therapeutics – to enter similar relationships, keeps an Outperform rating and $12 price target on GoodRx shares.